Skip to main content

Table 3 PIK3CA correlation analysis

From: Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

 

PIK3CAmutant

PIK3CAwild-type

n

Pvalue

ER at diagnosis

    

   Positive

14

18

32

0.0082

   Negative

1

16

17

 

HER2 at diagnosis

    

   Positive

2

13

15

0.17

   Negative

12

21

33

 

ER at recurrence

    

   Positive

13

14

27

0.0076

   Negative

3

21

24

 

HER2 at recurrence

    

   Positive

1

11

12

0.79

   Negative

14

24

38

 
  1. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us